Evolving role of MRD negativity in multiple myeloma

The evolving role of autologous transplantation in multiple myelomaПодробнее

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее

Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple MyelomaПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

The evolving role of maintenance therapy post-ASCT in MMПодробнее

The increasing use of MRD to personalize therapy for multiple myeloma in clinical practiceПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma, Dana-Farber Cancer InstituteПодробнее

MCRT Baltimore 2018: Evolution of Multiple Myeloma by Ivan Borrello, MDПодробнее

Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer InstituteПодробнее

Dr Robert Hensen: Advances in multiple myeloma (part 1)Подробнее

Multiple Myeloma: A Pathway to Better OutcomesПодробнее

Newly Diagnosed Multiple Myeloma, Response, Bone Health, Renal Health, MRD, Survivorship CareПодробнее

What are new treatment options for newly-diagnosed multiple myeloma patients? Dr. Paul G. RichardsonПодробнее